INTRODUCTION
Red ® -X goat anti-rabbit Ig G (H+L) conjugate (Molecular Probes). Alternatively, cells were treated for 1 h at room temperature with a monoclonal IgM antibody against glycogen, a generous gift from Dr. O. Baba (26) , diluted in PBS containing 3 % bovine serum albumin (w/v), washed with PBS and subjected to incubation for 30 min with a goat anti-mouse IgM secondary antibody conjugated to tetrametylrhodamine (Chemicon).
For actin staining, hepatocytes were treated for 30 min with fluorescein conjugated phalloidin (Molecular Probes). Coverslips were finally air-dried and mounted on glass microscope slides using Immuno Floure Mounting Medium (ICN Biomedicals, Inc.). Fluorescence images were obtained with a Leica TCS 4D (Leica Lasertechnik, Heidelberg, Germany) confocal scanning laser microscope adapted to an inverted Leitz DMIRBE microscope and a 63 x (NA 1.4 oil) Leitz Plan-Apo objective.
The light source was an argon/krypton laser (75 mW) and optical sections (0.1 µm)
were obtained.
Electrophoresis and Immunoblotting -Active and total liver glycogen phosphorylase (GP) protein levels were measured in hepatocyte homogenates by Western blot. Electrotransfer of proteins from the gel to the nitrocellulose was performed at 200 V (constant) and room temperature for 2 h, using a Bio-Rad miniature transfer apparatus, as described (27) . The nitrocellulose blots were incubated overnight at 4ºC in blocking buffer (1 % BSA, 0.05 % Tween-20 in phosphate-buffered saline).
Blots were then incubated for 1 h with antibodies against phosphorylated (active) or total GP. The antibody against active GP was raised in chicken using the peptide
RESULTS

Effect of DHA on glycogen metabolism -We evaluated glycogen deposition in
hepatocytes that were synthesizing glucose from DHA by gluconeogenesis. Hepatocytes were maintained for 16 h in a medium devoid of glucose and DHA and then incubated for 2 h with increasing concentrations of DHA. These cells showed a dose-dependent increase in glycogen content (Fig. 1A) , intracellular Glc-6-P concentration (Fig. 1B ) and active GS levels (Fig. 1C) , whereas total GS activity did not change in any of the conditions assayed (data not shown). These effects were maximal at 10 mM DHA ( Fig.   1 ) and, therefore, this concentration of the gluconeogenic precursor was chosen to perform subsequent experiments.
Effect of DHA on the subcellular distribution of GS and glycogen deposition -To
examine the effect of DHA on the intracellular distribution of hepatic GS, cultured hepatocytes were incubated for 2h in the presence of 10 mM DHA, 10 mM glucose and, 25 mM glucose, or left untreated. Immunofluorescence analysis, using an antibody that specifically recognizes liver GS (6) , showed that incubation with DHA produced an accumulation of the enzyme at the periphery of the hepatocytes, similar to that observed after glucose treatment. In control cells, GS was distributed throughout the cytoplasm and after incubation with glucose or DHA, the enzyme formed patches near the hepatocyte plasma membrane (Fig 2A) .
Immunodetection of glycogen particles with a monoclonal anti-glycogen antibody (26) showed that DHA also induced the deposition of the polysaccharide at the cell periphery, as observed with the hepatocytes incubated with glucose (Fig. 2B) .
Effect of GS overexpression on hepatocytes incubated with DHA or glucose -In control uninfected hepatocytes, a 2 h-treatment with 10 mM DHA induced the deposition of 16.1 ± 0.6 µg of glycogen/10 6 cells. This value was 40 % lower than that measured for hepatocytes incubated with 25 mM glucose (28.1 ± 0.6 µg of glycogen/10 6 cells) (Fig. 3A) , even though the levels of Glc-6-P and active GS were somewhat higher in the former condition (Fig. 3B,C ).
When total GS was overexpressed 4-fold by treatment of cultured hepatocytes with the AdCMV-RLGS adenovirus (Table I) , the ability of these cells to accumulate glycogen increased substantially. However, the differences in glycogen content with the respective uninfected controls were higher in the glucose-treated hepatocytes than in those incubated with 10 mM DHA. Thus, GS-overexpressing hepatocytes treated with 5 or 25 mM glucose accumulated approximately 160 % more glycogen than their corresponding controls and reached a level of 73 ± 10 µg/10 6 cells at 25 mM glucose (Fig. 3A) . In contrast, AdCMV-RLGS-infected hepatocytes incubated with 10 mM DHA deposited 28 ± 3 µg glycogen/10 6 cells, which is only 70 % higher than that observed for their uninfected counterparts, and represents 40 % of the glycogen accumulated by GS-overexpressing hepatocytes treated with 25 mM glucose. This large difference was observed in spite of the fact that intracellular Glc-6-P concentration ( Fig.   3B ) and active GS levels ( Fig. 3C) were similar in AdCMV-RLGS-infected hepatocytes incubated with 25 mM glucose or with 10 mM DHA.
On the other hand, the increase in glycogen content observed in GSoverexpressing hepatocytes incubated with DHA was accompanied by a 13 % decrease in the glucose output, which changed from 215 ± 5 to 188 ± 2 µg glucose/10 6 cells in uninfected and GS-overexpressing cells, respectively.
Effect of GK overexpression on hepatocytes incubated with DHA or glucose -A 3-fold overexpression of GK (Table I) caused an increase of about 120% in the intracellular Glc-6-P concentration of cultured hepatocytes treated with 5 (0.45 ± 0.10 nmol Glc-6-P /10compared with their uninfected controls (0.21 ± 0.05 and 0.66 ± 0.07 nmol Glc-6-P /10 6 cells, respectively) (Fig. 3B) . As a result, the levels of active GS (1.74 ± 0.07 and 2.10 ± 0.16 mU/10 6 cells, respectively) ( Fig. 3C ) and glycogen content (31.7 ± 3.4 and 67.2 ± 6.9 µg/10 6 cells, respectively) (Fig. 3A) of AdCMV-GK infected hepatocytes treated with 5 or 25 mM glucose also rose significantly and in a glucose-concentration dependent manner, as described previously (1).
In contrast, GK overexpression did not affect the Glc-6-P concentration of hepatocytes treated with 10 mM DHA (0.80 ± 0.05 nmol Glc-6-P /10 6 cells in uninfected hepatocytes vs. 0.86 ± 0.14 nmol Glc-6-P /10 6 cells in AdCMV-GK-treated hepatocytes) (Fig. 3B) . Accordingly, the levels of active GS (1.47 ± 0.06 and 1.43 ± 0.16 mU/10 6 cells, respectively) ( 
Effect of G6Pase overexpression on hepatocytes incubated with DHA or glucose
-The ability of hepatocytes to accumulate glycogen was drastically reduced when G6Pase was overexpressed 3-fold in these cells (Table I) . Cultured hepatocytes treated with AdCMV-G6Pase and incubated with 10 mM DHA, 5 mM or 25 mM glucose showed a decrease of 75, 35, and 50 % in glycogen content, respectively, compared to their uninfected controls (Fig. 3A) . The larger drop in glycogen accumulation in hepatocytes incubated with 10 mM DHA was consistent with the larger effect of the overexpression of G6Pase on Glc-6-P concentration and active GS levels in these cells, which were respectively 25 % and 45 % of those determined for the uninfected controls which were determined in previous experiments, were plotted against the corresponding Glc-6-P concentration values. The points derived from hepatocytes infected with the AdCMV-RLGS adenovirus were not included in the plots, since in these experiments the total amount of GS was artificially augmented and, therefore, they are not comparable with the rest of the series, as we previously pointed out (1).
There was a strong correlation between the levels of active GS and Glc-6-P concentration, irrespective of the origin of this metabolite. This linear correlation held throughout the range of Glc-6-P concentrations, from the lowest values, attained by means of G6Pase overexpression, to the highest, obtained in GK overexpressing hepatocytes (Fig. 4B) .
However, when glycogen content was plotted against Glc-6-P concentration, two sets of points were clearly distinguishable (Fig. 4A) . The points corresponding to hepatocytes incubated with glucose or with DHA fell in two separate straight lines with distinct slopes. Thus, the sensitivity of glycogen deposition to intracellular Glc-6-P concentration, measured as the slope of the plot, is about two-fold higher in cultured hepatocytes incubated with glucose than in those treated with DHA (Fig. 4A ).
Activation state of glycogen phosphorylase in hepatocytes incubated with DHA
or glucose -To determine whether incubation with glucose or DHA affected the levels of total or active glycogen phosphorylase (GP), we performed Western blot analysis of hepatocyte homogenates, using two antibodies directed respectively against two unrelated peptides contained in the sequence of rat liver GP. The first antibody, which was raised against a peptide that consists of the 22 C-terminal amino acids of the protein, was used to provide a measure of total GP. In Western blots the immune, but not the pre-immune serum, recognized a band of the expected molecular mass in rat liver extracts, but not in muscle homogenates (data not shown). Muscle expresses a different GP isoform, which does not contain in its sequence the peptide used for the immunizations of the rabbits. The second antibody was raised in chicken against an 11 amino acid peptide, which includes the phosphorylated Ser residue at position 15 of the rat liver GP, and it also recognized a band of the expected molecular mass in liver extracts. This band was more intense in Western blots of homogenates from cultured hepatocytes treated with 100 µM forskolin, a drug that is known to trigger the phosphorylation and, thus the activation, of GP through an increase in the intracellular levels of cAMP (Fig. 5A ). The binding of this antibody to active GP was blocked by the presence of the phosphorylated peptide used for the immunizations, but not by the analogous peptide in which the critical Ser residue (Ser15) is not phosphorylated (Fig.   5A ). These observations indicate that the phospho-specific antibody only recognizes the active phosphorylated form of liver GP.
Western blot analysis of cultured hepatocytes showed that the levels of total GP remained essentially unchanged in the incubations with 10 mM DHA, 5 mM or 25 mM glucose, compared to control cells (Fig. 5B) . However, while the levels of active GP in control cells and those incubated for 2 h with 10 mM DHA did not significantly change,
DISCUSSION
In previous reports we have shown that Glc-6-P produced by GK in cultured hepatocytes (13, 28) and in FTO2B cells (14) is more effective in promoting the covalent activation of hepatic GS and the deposition glycogen than Glc-6-P derived from the catalytic action of HK I. This result suggested that Glc-6-P is compartmentalized in at least two pools in these cells. Liver GS is excluded from the compartment where the Glc-6-P produced by HK I is directed, while it has access to the Glc-6-P pool replenished by the GK-mediated phosphorylation of glucose. This second pool is also accessible to other enzymes and provides substrate for several metabolic routes. Thus, overexpression of GK enhances not only glycogen deposition, but also glycolysis, both in cultured hepatocytes (28) and in FTO2B cells (29) . Glc-6-P from this pool can also be directed to hydrolysis by G6Pase, since overexpression of the catalytic subunit of this system reduces glycogen deposition and lactate production, while it increases hydrolysis of Glc-6-P (21).
The main conclusion of this study is that the gluconeogenic pathway and the direct phosphorylation of glucose by GK deliver their common product to the same "general" Glc-6-P pool, which feeds the above mentioned metabolic processes. The activation state of GS strongly correlates with the intracellular levels of Glc-6-P in hepatocytes incubated with glucose (3, 30, 31) . As shown in the present study, this positive correlation also holds when cultured hepatocytes are incubated with gluconeogenic precursors, such that Glc-6-P arising from gluconeogenesis is as effective in activating hepatic GS as Glc-6-P produced by GK (Fig. 4B) . The conversion of Glc-6-P into glucose by G6Pase and later re-phosphorylation to Glc-6-P prior to triggering the covalent activation of GS can be ruled out since, in contrast to what occurs in hepatocytes incubated with glucose, GK overexpression has negligible effects on GS activation and glycogen deposition in hepatocytes incubated with DHA (Fig. 3) .
However, although liver GS activation state is equally sensitive to Glc-6-P produced by GK or by gluconeogenesis, glycogen accumulation in cultured hepatocytes is more efficient when Glc-6-P originates from direct phosphorylation of glucose by GK (Fig. 4A) . Similar levels of Glc-6-P attained by treating hepatocytes with glucose or with DHA have distinct quantitative effects on glycogen deposition. An explanation for this could reside in the observation that while incubation with DHA has the main effect of increasing intracellular Glc-6-P concentration, treatment with glucose simultaneously triggers the partial dephosphorylation and inactivation of GP ( Through the use of GP inhibitors which cause its inactivation by dephosphorylation, it has been shown (15,33,34) that active GP plays a role in controlling the phosphorylation state of GS. The covalent inactivation of GP relieves glycogen synthase phosphatase from the allosteric inhibition caused by active GP, thus leading to the dephosphorylation and activation of GS (2). However, in our experimental conditions, the levels of active GS strongly correlate with the intracellular Glc-6-P concentration, regardless of the GP activation state, indicating that GP inactivation is not a prerequisite for the covalent activation of GS. An identical conclusion was obtained from two previous studies in which the treatment with fructose (35) or lithium chloride (36) of hepatocytes isolated from fasted rats led to the simultaneous activation of GS and GP. These two apparently contradictory conclusions may be reconciled by assuming that the levels of active GP do have an effect in determining the GS activation state, as long as the intracellular concentration of Glc-6-P remains constant. However, an increase in the Glc-6-P concentration would override the allosteric inhibition of glycogen synthase phosphatase by active GP, thus causing a corresponding increase in the levels of active GS in cultured hepatocytes.
Our results also suggest that the lower efficiency shown by Glc-6-P produced by gluconeogenesis in stimulating glycogen deposition could be attributed to a futile cycle through GS and GP, since both enzymes co-exist as their respective active forms in hepatocytes incubated with DHA. Glycogen cycling has been shown to occur in vivo and in vitro by several techniques that include the utilization of stable or radioactive isotopes (37-40) or selective GP inhibitors (41) . Meijer and coworkers (15, 40) have analyzed how the degree of glucose cycling, through GK and G6Pase, and glycogen cycling affect glycogen accumulation in isolated hepatocytes. By means of acute inhibition of the hepatic G6Pase system with S4048, a chlorogenic acid derivative that inhibits translocation of Glc-6-P across the endoplasmic-reticulum membrane, these authors have altered the partitioning of Glc-6-P produced by gluconeogenesis into glucose production and storage as glycogen. This partitioning can also be modulated by the overexpression of the enzymes involved in this metabolism. Thus, GS overexpression in cultured hepatocytes re-directs part of the Glc-6-P produced by gluconeogenesis from DHA to glycogen deposition, with the consequent reduction of glucose output. Conversely, the overexpression of the catalytic subunit of G6Pase has opposite effects.
Another point that we have addressed in this paper is the study of the subcellular distribution of hepatic GS. We have previously shown that incubation of isolated (5) or cultured hepatocytes (6) with glucose causes the translocation of GS from the cytoplasm to the cell periphery, where initial glycogen synthesis takes place. When added to cultured hepatocytes, DHA has the same effect as glucose on the localization of GS and the pattern of glycogen deposition. We propose that Glc-6-P is the key metabolite that controls the subcellular distribution of hepatic GS, such that an increase in the intracellular concentration of Glc-6-P triggers the accumulation of GS at the hepatocyte periphery. This is based in the following reasoning.
First, the mere activation of GS induced by treatment with lithium chloride, a known inhibitor of glycogen synthase kinase-3 (42, 43), is not sufficient to cause GS translocation to the hepatocyte periphery (6) . Second, the common metabolites in the biosynthetic pathway of glycogen from glucose and from gluconeogenic precursors are Glc-6-P, which is in equilibrium with Glc-1-P, and UDP-Glc, the substrate of GS and immediate precursor in glycogen synthesis . Of these three intermediates, UDP-Glc can be ruled out as the signal molecule, since its intracellular concentration appears to be buffered and remains unchanged upon wide variations of Glc-6-P. Thus, GK (1) and G6Pase (21) overexpression in cultured hepatocytes led, respectively, to a large increase or decrease in the Glc-6-P levels, which in turn translated into increased or decreased glycogen accumulation. However, the intracellular concentration of UDP-Glc did not significantly change in any of these situations. Third, Glc-6-P is involved in the control of the aggregation state of hepatic GS and its translocation from a soluble form to a form that sediments at low centrifugal forces, both in isolated hepatocytes (44) and in vivo (31) . 
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